Search Patents
  • IMMUNOASSAY FOR SARS-COV-2 AND MATERIALS THEREFOR
    Publication number: 20220326240
    Abstract: The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.
    Type: Application
    Filed: April 8, 2022
    Publication date: October 13, 2022
    Inventors: RAVI KAUL, SHUXIA ZHOU, ROGER P. WALKER
  • OPTICAL COVID-19 DETECTION SYSTEM
    Publication number: 20220299506
    Abstract: The disclosure provides example devices and methods for making and using the devices for rapid testing for the SARS-CoV-2 virus. The example device includes (a) a substrate coupled to a metal oxide layer, (b) a graphene layer coupled to the metal oxide layer, (c) a chemical or biochemical linker functionalized with the graphene layer, and (d) a plurality of SARS-CoV-2 receptors that are bound to the graphene layer via the chemical or biochemical linker, wherein the plurality of SARS-CoV-2 receptors comprise SARS-CoV-2 spike antibodies or SARS-CoV-2 spike proteins, where the graphene layer is configured to have a first phononic energy, when the plurality of SARS-CoV-2 receptors are unattached to target molecules, and a second phononic energy, when the plurality of SARS-CoV-2 receptors are attached to target molecules.
    Type: Application
    Filed: March 16, 2022
    Publication date: September 22, 2022
    Inventors: Vikas Berry, Lan Nguyen, Sungjoon Kim
  • Coronavirus disease (COVID-19) vaccine
    Patent number: 11660336
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: May 30, 2023
    Assignee: Thomas Jefferson University
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • IMMUNE MEMORY ENHANCED PREPARATIONS AND USES THEREOF
    Publication number: 20220062406
    Abstract: Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation/preparations may comprise a target infectious agent protein/peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide/protein antigen or peptide or fragment thereof).
    Type: Application
    Filed: August 27, 2021
    Publication date: March 3, 2022
    Inventors: Mark Suckow, Ashley Kalinauskas, Ryan Michael Clauson
  • ANTIBODIES
    Publication number: 20230265170
    Abstract: The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 24, 2023
    Inventors: Juthathip MONGKOLSAPAYA, Gavin SCREATON
  • ANTIBODIES
    Publication number: 20240043507
    Abstract: The present invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2, and methods and uses thereof in the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19.
    Type: Application
    Filed: February 4, 2022
    Publication date: February 8, 2024
    Inventors: Gavin SCREATON, Juthathip MONGKOLSAPAYA
  • Coronavirus disease (COVID-19) vaccine
    Patent number: 11975067
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: May 7, 2024
    Assignee: Thomas Jefferson University
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2
    Publication number: 20230399385
    Abstract: Provided is a novel neutralizing antibody against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 14, 2023
    Inventors: Bai LU, Yang DOU, Lin CAO, Xiaoyu XU, Jianfeng PAN
  • Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
    Publication number: 20060240551
    Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
    Type: Application
    Filed: February 8, 2006
    Publication date: October 26, 2006
    Inventors: Shibo Jiang, Yuxian He
  • METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING COVID-19 INFECTION AND RELATED INFLAMMATION
    Publication number: 20230391837
    Abstract: The present disclosure relates in part to methods of treating, preventing, and/or ameliorating SARS-CoV-2 infection and/or related inflammatory syndromes by administration of a Maackia amurensis seed lectin (MASL). MASL has a strong affinity for sialic acid modified proteins and may be used as an antiviral agent. This lectin targets the ACE2 receptor, decreases ACE2 expression and glycosylation, suppresses binding of the SARS-CoV-2 spike protein, and decreases expression of inflammatory mediators by oral epithelial cells that cause ARDS in COVID-19 patients.
    Type: Application
    Filed: October 19, 2021
    Publication date: December 7, 2023
    Applicant: Rowan University
    Inventors: Gary S. Goldberg, Paola Leone
  • METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19
    Publication number: 20230129326
    Abstract: Methods of preventing or treating infection by a SARS-CoV-related betacoronavirus are described. The methods include administering to a patient at risk of being infected by a SARS-CoV-related betacoronavirus or suffering from SARS-CoV-related betacoronavirus-related illness a small molecule drug and/or an antibody that binds to the ACE2-SARS interaction domain of either ACE2 or SARS-CoV-2 spike protein. Also described are vaccines comprising S-protein polypeptides corresponding to the ACE-2 interaction domain.
    Type: Application
    Filed: April 6, 2021
    Publication date: April 27, 2023
    Inventors: David A. OSTROV, Leah R. REZNIKOV, Michael NORRIS, Ashley Nicole BROWN
  • ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
    Publication number: 20230220053
    Abstract: Disclosed herein are anti-SARS-CoV-2 spike protein antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such antibodies.
    Type: Application
    Filed: May 17, 2021
    Publication date: July 13, 2023
    Applicant: Elpis Biopharmaceuticals
    Inventors: Yan CHEN, Kehao ZHAO, Jenna NGUYEN, Ning JIANG
  • METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTION
    Publication number: 20230331815
    Abstract: The disclosure provides methods for treating or preventing coronavirus infection comprising administration of a therapeutically effective amount of lactoferrin or a therapeutically effective amount of a protein fusion comprising recombinant lactoferrin fused to the receptor binding domain of the SARS-CoV-2 spike protein. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin.
    Type: Application
    Filed: May 22, 2023
    Publication date: October 19, 2023
    Inventors: Jang Hyun HAN, William J. RUTTER, Mi-Young SEO
  • CORONAVIRUS VACCINES
    Publication number: 20230241201
    Abstract: The invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding the S1 and S2 subunits of a coronavirus Spike protein is located, such that a chimeric virus is expressed.
    Type: Application
    Filed: March 1, 2021
    Publication date: August 3, 2023
    Inventors: Kai DALLMEIER, Johan NEYTS, Lorena SANCHEZ FELIPE, Hendrik, Jan THIBAUT, Dominique VAN LOOVEREN, Thomas VERCRUYSSE
  • VACCINE FOR VIRAL PATHOGENS
    Publication number: 20230310585
    Abstract: The present invention provides vaccines against respiratory viruses including coronavirus, such as SARS-CoV-2, and influenza viruses. In particular, the present invention provides vaccines against SARS-CoV-2 which encode a targeting domain and a SARS-CoV-2 spike protein or fragment thereof.
    Type: Application
    Filed: September 13, 2021
    Publication date: October 5, 2023
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventor: Wilfred JEFFERIES
  • A VACCINE AGAINST SARS-COV-2 AND PREPARATION THEREOF
    Publication number: 20230174588
    Abstract: The current invention provides a DNA construct comprising S gene or S1 gene region of 2019-nCoV spike-S protein. The DNA construct of the present invention comprises DNA plasmid vector carrying S gene or S1 gene region of 2019-nCoV spike-S protein. The vector may further comprise a gene encoding IgE signal peptide or a gene encoding t-PA signal peptide. The DNA construct according to the present invention is further used in the preparation of an immunogenic composition or a vaccine for treating or preventing corona virus or its related diseases.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 8, 2023
    Inventor: Pankaj PATEL
  • CORONAVIRUSES EPITOPE-BASED VACCINES
    Publication number: 20180334480
    Abstract: Provided are polypeptides derived from the coronaviruses (CoVs) Spike protein (S) characterized by high affinity and specificity the S receptor and its neutralizing antibodies. Further provided are compositions and vaccines, and vaccine-based therapies targeting CoVs, and SARS and MERS viruses in particular.
    Type: Application
    Filed: September 15, 2016
    Publication date: November 22, 2018
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Jonathan GERSHONI
  • Method of detecting SARS-CoV-2 cleavage targeted proprotein convertase and facilitated protease activity
    Publication number: 20220049283
    Abstract: The present invention provides the methods of detecting the cleavage activity of PCs and proteases that are in purified form or from a biological sample and target to SARS-CoV-2 spike protein cleavage.
    Type: Application
    Filed: August 14, 2020
    Publication date: February 17, 2022
    Inventors: Weiwei Li Li, Jessica Mliu Li, William Lei Lee
  • HYBRID ALPHAVIRUS-SARS-COV-2 PARTICLE AND METHODOLOGY OF MAKING AND USING SAME
    Publication number: 20220119776
    Abstract: Timely development of vaccines and antiviral drugs is critical to control the COVID-19 pandemic. Current methods for quantifying vaccine-induced neutralizing antibodies involve the use of pseudoviruses, such as the SARS-CoV-2 spike protein (S) pseudotyped lentivirus. However, these pseudoviruses contain structural proteins foreign to SARS-CoV-2, and require days to infect and express reporter genes. Here, the present application discloses composition and methodology for making and using a new hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) particle for rapid and accurate quantification of neutralization antibodies and viral variants.
    Type: Application
    Filed: October 19, 2021
    Publication date: April 21, 2022
    Inventors: Brian HETRICK, Yuntao WU
  • A Method of Detecting SARS-COV2 Antibodies and Related Products
    Publication number: 20230296604
    Abstract: There is provided a method of identifying/characterising coronavirus infection in a human subject. In a specific embodiment the method comprising contacting a serum sample from the subject with an isolated host cell expressing a nucleotide that encodes for a codon optimised gene for SARS-CoV-2 spike protein (S protein); and detecting a binding of an antibody or an antigen-binding fragment thereof to said host cell using a flow cytometry and a labelled anti-human secondary antibody. Also disclosed is a method of identifying a subject having immunity for coronavirus, especially SARS-CoV-2 wherein a sample from a subject is incubated with said cell and is detected using the flow cytometry and the labelled anti-human secondary antibody. Nucleic acid encoding a SARS-CoV-2 S protein, viral vectors and host cells thereof are also disclosed.
    Type: Application
    Filed: September 21, 2021
    Publication date: September 21, 2023
    Inventors: Yun Shan Goh, Laurent Renia, Lisa Fong Poh Ng
Narrow Results

Filter by US Classification